{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T10:25:27Z","timestamp":1787307927921,"version":"build-2736575974"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"1211","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2022CDJYGRH-016"],"award-info":[{"award-number":["2022CDJYGRH-016"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Alopecia areata (AA), an autoimmune disorder, represents a prevalent form of hair loss among individuals. Various therapeutic approaches exist for managing AA, with Janus kinase (JAK) inhibitors emerging as a promising treatment modality. Nonetheless, there is a paucity of rigorous studies directly comparing the efficacy of JAK inhibitors in cases of severe AA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Evaluating the efficacy of different JAK inhibitors in the treatment of severe AA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A comprehensive search was conducted across four databases\u2014PubMed, Embase, Web of Science, and Cochrane Library\u2014on February 10, 2025. Eligible studies were selected based on the PICOS framework. A Bayesian network meta-analysis was employed to extract and analyze data concerning the number of individuals achieving SALT20 and corresponding sample sizes. The relative efficacy of the interventions was evaluated using league tables and Surface Under the Cumulative Ranking values.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>A total of 3866 patients with AA were included in the study, with a total of 10 interventions. Of these, the one that showed the best efficacy was deuruxolitinib_12\u00a0mg, but with wider 95% confidence intervals. Of all the JAK inhibitors, the one with significant efficacy and high precision of results was baricitinib_4\u00a0mg (OR: 2.59, 95% CI: 1.98\u20133.38).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The efficacy of JAK inhibitors in the treatment of severe AA is definitive, and all possess a dose-dependent effect. This study provides valuable insights for clinicians in selecting appropriate pharmacological interventions for severe AA.<\/jats:p>\n                    <jats:p>Key messages What is already known on this topic: Alopecia areata is an autoimmune disorder characterized by patchy hair loss on the scalp. Previous studies have demonstrated that JAK inhibitors can effectively treat alopecia areata, but research comparing the efficacy of different JAK inhibitors is lacking. What this study adds: This study established a ranking of efficacy for different JAK inhibitors in treating severe alopecia areata, providing a reference for selecting clinical treatment regimens. How this study might affect research, practice, or policy: Future studies are needed to directly compare the efficacy of different JAK inhibitors in treating alopecia areata. This will provide more reliable evidence for formulating treatment regimens for alopecia areata.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/postmj\/qgaf189","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:21:20Z","timestamp":1761222080000},"page":"855-861","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy of Janus kinase inhibitors in severe alopecia areata: a network meta-analysis based on randomized controlled trials"],"prefix":"10.1093","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7610-2990","authenticated-orcid":false,"given":"Yinfeng","family":"Xia","sequence":"first","affiliation":[{"name":"Department of Burns, Plastic Surgery and Cosmetology, Chongqing University Fuling Hospital , Chongqing University, Chongqing,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Chen","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Chongqing Medical University , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Burns, Plastic Surgery and Cosmetology, Chongqing University Fuling Hospital , Chongqing University, Chongqing,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Burns, Plastic Surgery and Cosmetology, Chongqing University Fuling Hospital, Chongqing University , Chongqing,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"2026082105415469800_ref1","first-page":"397","article-title":"Epidemiology and burden of alopecia areata: a systematic review","volume":"8","author":"Villasante Fricke","year":"2015","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2026082105415469800_ref2","first-page":"59","article-title":"Alopecia areata\u2014current understanding and management","volume":"20","author":"Lintzeri","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"key":"2026082105415469800_ref3","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/1346-8138.17064","article-title":"Alopecia areata: what's new in the diagnosis and treatment with JAK inhibitors?","volume":"51","author":"Dainichi","year":"2024","journal-title":"J Dermatol"},{"key":"2026082105415469800_ref4","doi-asserted-by":"crossref","first-page":"adv00855","DOI":"10.2340\/actadv.v103.4536","article-title":"Comparative efficacy and safety of Janus kinase inhibitors used in alopecia areata: a systematic review and meta-analysis","volume":"103","author":"Barati Sedeh","year":"2023","journal-title":"Acta Derm Venereol"},{"key":"2026082105415469800_ref5","doi-asserted-by":"crossref","first-page":"e2320351","DOI":"10.1001\/jamanetworkopen.2023.20351","article-title":"Janus kinase inhibitors for alopecia areata: a systematic review and meta-analysis","volume":"6","author":"Liu","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026082105415469800_ref6","doi-asserted-by":"crossref","first-page":"955035","DOI":"10.3389\/fimmu.2022.955035","article-title":"An overview of JAK\/STAT pathways and JAK inhibition in alopecia areata","volume":"13","author":"Lensing","year":"2022","journal-title":"Front Immunol"},{"key":"2026082105415469800_ref7","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"key":"2026082105415469800_ref8","first-page":"107723","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2025 update","volume":"2025","author":"Jr Roskoski","journal-title":"Pharmacol Res"},{"key":"2026082105415469800_ref9","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"2026082105415469800_ref10","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jaad.2017.10.048","article-title":"Objective outcome measures: collecting meaningful data on alopecia areata","volume":"79","author":"Olsen","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2026082105415469800_ref11","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/bjd.18883","article-title":"The alopecia areata investigator global assessment scale: a measure for evaluating clinically meaningful success in clinical trials","volume":"183","author":"Wyrwich","year":"2020","journal-title":"Br J Dermatol"},{"key":"2026082105415469800_ref12","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s40265-023-01873-w","article-title":"Baricitinib for the treatment of alopecia areata","volume":"83","author":"Freitas","year":"2023","journal-title":"Drugs"},{"key":"2026082105415469800_ref13","doi-asserted-by":"crossref","first-page":"465","DOI":"10.4103\/idoj.idoj_452_22","article-title":"Which is the ideal JAK inhibitor for alopecia areata\u2014baricitinib, tofacitinib, ritlecitinib or ifidancitinib\u2014revisiting the immunomechanisms of the JAK pathway","volume":"14","author":"Sardana","year":"2023","journal-title":"Indian Dermatol Online J"},{"key":"2026082105415469800_ref14","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1111\/jocd.15903","article-title":"The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: network meta-analyses of clinical trials","volume":"22","author":"Gupta","year":"2023","journal-title":"J Cosmet Dermatol"},{"key":"2026082105415469800_ref15","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/jdv.19797","article-title":"Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: a systematic review and Bayesian network meta-analysis","volume":"38","author":"Husein-Elahmed","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026082105415469800_ref16","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jaad.2021.05.050","article-title":"Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: phase 2 results from a randomized controlled study","volume":"85","author":"King","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2026082105415469800_ref17","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","article-title":"A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results","volume":"85","author":"King","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2026082105415469800_ref18","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King","year":"2022","journal-title":"N Engl J Med"},{"key":"2026082105415469800_ref19","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jaad.2022.03.045","article-title":"Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus kinase inhibitor, in moderate-to-severe alopecia areata","volume":"87","author":"King","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2026082105415469800_ref20","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40257-023-00764-w","article-title":"Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2)","volume":"24","author":"Kwon","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"2026082105415469800_ref21","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/pde.15378","article-title":"Efficacy and safety of ritlecitinib in adolescents with alopecia areata: results from the ALLEGRO phase 2b\/3 randomized, double-blind, placebo-controlled trial","volume":"40","author":"Hordinsky","year":"2023","journal-title":"Pediatr Dermatol"},{"key":"2026082105415469800_ref22","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jaad.2024.06.097","article-title":"Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: results from the phase 3 randomized, controlled trial (THRIVE-AA1)","volume":"91","author":"King","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2026082105415469800_ref23","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1111\/1346-8138.17442","article-title":"Efficacy and safety of ritlecitinib, an oral JAK3\/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis","volume":"51","author":"Mesinkovska","year":"2024","journal-title":"J Dermatol"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/102\/1211\/855\/68684748\/qgaf189.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/102\/1211\/855\/68684748\/qgaf189.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T09:42:02Z","timestamp":1787305322000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/102\/1211\/855\/8723849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":23,"journal-issue":{"issue":"1211","published-online":{"date-parts":[[2026,7,2]]},"published-print":{"date-parts":[[2026,8,21]]}},"URL":"https:\/\/doi.org\/10.1093\/postmj\/qgaf189","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,7,2]]}}}